Highlights of Annual Results for the Year Ended

年度业绩亮点

December 31, 2024

2024年12月31日

Revenue reached

收入达到

RMB1,986.7 million

人民币1986.7百万元

Gross profit amounted to

毛利润总计

RMB687.4 million

6亿8740万元人民币

Net profit recorded

记录的净利润

RMB222.0 million

2.22亿元人民币

, a significant turnaround from a year ago

显著扭转了去年的局面

Adjusted Non-IFRS net profit recorded

调整后非国际财务报告准则净利润记录

RMB314.6 million

人民币3.146亿元

, a YOY increase of nearly 50.6%.

，同比增长近50.6%。

SHANGHAI

上海

,

，

March 27, 2025

2025年3月27日

/PRNewswire/ -- On

/PRNewswire/ -- 在

March 27, 2025

2025年3月27日

, Viva Biotech Holdings ('Viva Biotech', 'the Group' or 'the Company', stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved

，维亚生物科技控股集团（“维亚生物”，“集团”或“公司”，股票代码：1873.HK）宣布，集团在报告期间内的收入达到

RMB1,986.7 million

人民币1986.7百万元

, gross profit amounted to

，毛利润达到

RMB687.4 million

人民币687.4百万元

and net profit recorded

并记录净利润

RMB222.0 million

人民币2.22亿元

, a significant turnaround from a net loss of

，与净亏损相比有了显著的转变

RMB99.8 million

9980万元人民币

in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convertible bonds, and an increase in adjusted non-IFRS net profit to

去年同期，主要受益于可转债的全额偿还导致相关财务调整的消除，以及非国际财务报告准则调整后净利润的增长。

RMB314.6 million

人民币3.146亿元

from

从

RMB208.8 million

2.088亿元人民币

in the corresponding period of last year, representing an increase of nearly 50.6% as compared to last year, which was mainly attributable to an increase in operating profit margin driven by the recovery of CRO business growth and the improving operational efficiency in 2H2024, as well as the recognition of investment income from milestone payments received by the Group during the year..

去年的相应期间相比，增长近50.6%，这主要得益于CRO业务增长复苏带来的营业利润率提升、2024年下半年运营效率的改善，以及集团在年内收到的里程碑付款所带来的投资收益确认。

In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on

此外，集团子公司上海维亚生物技术有限公司成功重组为股份有限公司。

September 27, 2024

2024年9月27日

, as the Group currently holds approximately 72.9% of its total issued share capital. During the Reporting Period, the Group's management and its strategic investors commenced a number of collaborations with full mutual trust, fully utilizing the strategic investors' strengths in global vision, capital markets and strategic resources to empower the Group's continuous enhancement in corporate governance, business operations, investment and financing as well as strategic planning..

，因为该集团目前持有其已发行股份总数的约72.9%。在报告期间内，集团管理层与战略投资者基于充分的信任展开了多项合作，充分利用战略投资者在全球视野、资本市场和战略资源方面的优势，助力集团在公司治理、业务运营、投融资以及战略规划等方面的持续提升。

CRO Revenue Growth Improved Significantly Improving in the Second Half of the Year to Sustain a Recovery Momentum Ahead

CRO收入增长在下半年显著改善，以保持复苏势头

In 2024, the revenue of the Company's CRO business decreased by approximately 4.0% to

2024年，公司CRO业务的收入下降了约4.0%，降至

RMB810.9 million

人民币8.109亿元

from

从

RMB844.9 million

人民币844.9百万元

in the same period of last year, while the corresponding adjusted gross profit decreased by approximately 1.9% to

去年同期，而相应的调整后毛利润下降了约1.9%，至

RMB357.1 million

357.1百万人民币

from

从

RMB363.8 million

人民币3.638亿元

in the same period of last year. The decrease in CRO revenue in 2024 as compared to previous years was mainly attributable to the short-term impact of the global biopharmaceutical investment and financing pressure in 2023 on the R&D investment in innovative drugs in 1H2024. However, with the gradual recovery of global biopharmaceutical investment and financing since 2024, the Company's CRO revenue in 2H2024 has realized positive year-on-year and quarter-on-quarter growth compared with the same period last year and the first half of 2024.

今年上半年，公司CRO收入较往年有所下降，主要系2023年全球生物制药投融资压力对2024年上半年创新药研发投入的短期影响所致。然而，随着2024年起全球生物制药投融资逐步回暖，公司2024年下半年CRO收入已实现同比、环比正增长。

In addition, the CRO order value has realized positive growth year-on-year, and the monthly new order value is still maintained at a high level, which will drive the Company's CRO revenue to further maintain the rebound trend in 2025. Meanwhile, the Company has also taken a series of effective measures to enhance operational efficiency to maintain the profitability of CRO at a higher level..

此外，CRO订单额同比已实现正增长，月度新增订单额仍保持在较高水平，这将推动公司CRO收入在2025年进一步保持反弹趋势。同时，公司还采取了一系列有效措施提升运营效率，以保持CRO业务的盈利能力在较高水平。

As of

截至

December 31, 2024

2024年12月31日

, the Company's cumulative number of CRO customers increased to 1,568, including the world's top 10 pharmaceutical companies (based on the total revenue of the 2024 annual report), with the revenue share of the top 10 customers accounting for 24.4%. The CRO business has a diversified geographical distribution of customers, with the revenue share from overseas regions accounting for approximately 87.3%.

公司累计CRO客户数量增加至1,568家，其中包括全球前十大制药企业（基于2024年年报总收入排名），前十名客户的收入占比为24.4%。CRO业务的客户地域分布多元化，其中来自海外地区的收入占比约为87.3%。

Revenue from customers in Mainland China accounted for approximately 12.7%..

来自中国大陆客户的收入约占12.7%。

As of the end of 2024, the Company has cumulatively delivered more than 82,716 protein structures to the clients, approximately 17,681 of which were newly delivered in 2024. The R&D of the Company has accumulated over 2,098 independent drug targets, 112 of which were newly delivered in 2024. Currently, the Company maintains a leading global position in the industry in the field of protein structure analysis.

截至2024年末，公司已累计向客户交付超过82,716个蛋白质结构，其中约17,681个为2024年新增交付。公司研发团队已累计完成超过2,098个独立药物靶点的研究，其中112个为2024年新增交付。目前，公司在蛋白质结构解析领域继续保持全球行业领先地位。

During the Reporting Period, the utilization of synchrotron radiation source reached 1,867 hours. The Company established long-term cooperation with 13 synchrotron radiation source centers around the world, the Company will ensure uninterrupted data collection throughout the year..

报告期内，同步辐射光源的使用时间达到1867小时。公司与全球13个同步辐射光源中心建立长期合作，保证全年无间断的数据收集。

In terms of marketing and business development, on one hand, the Company will obtain integrated service orders by fostering synergistic development of biological and chemical segments, on the other hand, the Company will actively continue to enhance the integration of digital marketing and offline business development (BD), while expanding its global BD team.

在市场与业务拓展方面，一方面公司将通过推动生物板块与化学板块协同发展获取整合服务订单，另一方面公司将积极推进数字营销与线下业务拓展（BD）相结合，同时扩充全球BD团队。

During the Reporting Period, the Group not only strengthened its presence in the European market, but also established a branch in .

在报告期间，集团不仅加强了其在欧洲市场的影响力，还在建立了分支机构。

Boston

波士顿

,

，

the United States

美国

. This marked a new milestone in the Company's global footprints, allowing us to further expand and deepen the international cooperation network. Moreover, the Company attaches great importance to the important role of artificial intelligence (AI) in drug R&D. Based on the efforts in improving efficiency and success rate, the Company combines dry and wet experiments to expand quantity and scale of new projects continuously.

这标志着公司全球足迹的一个新的里程碑，使我们能够进一步拓展和加深国际合作网络。此外，公司高度重视人工智能（AI）在药物研发中的重要作用。在提高效率和成功率的努力基础上，公司将干实验与湿实验相结合，不断扩大新项目的数量和规模。

It is worth mentioning that by the end of 2024, the Company had participated in 157 AIDD projects, and the cumulative number of customers purchasing CADD/AIDD reached 51. Revenue from AI-enabled projects exceeded .

值得一提的是，截至2024年底，公司累计参与AIDD项目157个，购买CADD/AIDD的客户数累计达到51家，AI赋能项目收入超过 。

US$10 million

1000万美元

, and cooperation with renowned institutions regarding a complete set of AI discovery solutions has been reached in some niche fields.

，与一些知名机构在整套人工智能发现解决方案上已经达成了合作，在某些小众领域。

New Commercial CDMO Projects to be Launched Soon

新的商业CDMO项目即将启动

and the CMC Business Optimization and Adjustment Largely Completed

并且CMC业务优化和调整大致完成

The Group is committed to building a one-stop service platform from R&D to production of global innovative drugs. Through the 100% equity interests acquisition of Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), the Group has been able to complete the deployment of the production side of the business.

集团致力于打造全球创新药从研发到生产的端到端服务平台。透过收购浙江朗华制药有限公司（朗华制药）100%的股权，集团得以完成业务生产端的部署。

During the Reporting Period, the Group continued to expand CDMO capacity to prepare for commercial production of new molecules in the future. In addition, the Company completed optimization and adjustment of the CMC business..

在报告期间，集团持续扩充CDMO产能，为未来新分子的商业化生产做准备。此外，公司完成了对CMC业务的优化与调整。

In 2024, Langhua Pharmaceutical recorded revenue of

2024年，朗华制药录得收入为

RMB1,175.7 million

人民币1175.7百万元

and the adjusted gross profit of

调整后的毛利润

RMB344.5 million

人民币3.445亿元

. As of

。截至

December 31, 2024

2024年12月31日

, Langhua Pharmaceutical had served 897 clients, with 66.8% of revenue accounted for by the top ten customers and 100% retention rate of the top ten customers. Currently, Langhua Pharmaceutical's CDMO business, in addition to the existing commercialized projects that can maintain natural growth, has two important new commercialized projects that are at the process performance qualification (PPQ) stage and are expected to be commercially launched in 2025 and 2026, respectively, which will serve as a new growth driver for the CDMO business in the future.

朗华制药累计服务客户897家，前十名客户占收入比重66.8%，前十名客户留存率100%。目前，朗华制药的CDMO业务除现有已商业化项目可保持自然增长外，还有两个重要的新增商业化项目，目前处于工艺性能确认（PPQ）阶段，预计分别于2025年、2026年实现商业化，将成为未来CDMO业务新的增长驱动。

With respect to production capacity, the current total available total capacity has reached 860 cubic meters. In addition, Langhua Pharmaceutical plans to establish a new production capacity of 400 cubic meters between 2024 and 2025 to cater the commercial production of new molecules, and the civil construction work has already been completed.

关于生产能力，目前总可用总产能已达到860立方米。此外，朗华制药计划在2024年至2025年期间新增400立方米的产能，以满足新分子的商业化生产，土建工程已经完成。

This endeavor will provide sufficient assurance for the Company's revenue growth with the launch of new products and release of reserved capacity in the future. Langhua Pharmaceutical will continue to adhere to the principles of customer first and regulatory compliance in quality management, strengthen cooperation with quality customers, and continuously improve and enhance the guidance and operability of the quality system.

此举将为公司未来新产品上市、预留产能释放提供充分的营收增长保障。朗华制药将继续秉持质量至上、合规经营的原则，加强与优质客户的合作，不断改进、提升质量体系的指导性和可操作性。

During the Reporting Period, Langham Pharmaceutical passed the on-site inspections of WHO and FDA again, which fully demonstrates that the quality system of Langham Pharmaceutical is further well aligned with the international system standards, and can guarantee the provision of quality, safe and reliable CDMO services to the world's leading pharmaceutical enterprises..

报告期内，朗华制药再次通过了世界卫生组织和美国食品药品管理局的现场检查，这充分表明朗华制药的质量体系进一步与国际体系标准接轨，能够为全球领先的制药企业提供优质、安全、可靠的CDMO服务。

In 2024, the Group adjusted its CMC business structure by focusing more on synthesis and analytics operations, strengthened BD efforts to overseas customers, and promoted continuous improvement in profitability through cost reduction, efficiency enhancement and customer mix optimization. Since its establishment, CMC has completed and is currently progressing with a total of 255 new drug projects, driven by a CMC R&D team of 105 members, and generated revenue of nearly .

2024年，集团调整了CMC业务结构，更加聚焦于合成与分析运营，强化对海外客户的BD推广力度，并通过降本增效和客户组合优化推动盈利能力持续提升。CMC自成立以来，累计完成及正在推进的新药项目共计255个，由105人的CMC研发团队驱动，创造收入近 。

RMB43.0 million

4300万元人民币

. In addition, the projects channeled by the Group progressed smoothly, and one pipeline has rapidly advanced to Phase III clinical trials, showcasing the success of the Group's integrated strategy. In the future, the Group will further strengthen the BD and channeling efforts for acquiring high-quality CMC projects with a view to promoting revenue growth and profitability improvement of the CMC business on the basis of fully utilizing internal project resources, reducing costs and increasing efficiency..

此外，集团引入的项目进展顺利，其中一条管线已迅速进入III期临床试验，彰显集团整合策略的成功。未来，集团将进一步加强BD和项目引入力度，获取更多优质CMC项目，从而在充分利用内部项目资源、降本增效的基础上，推动CMC业务收入增长和盈利能力提升。

Partial Exits of Incubation Portfolio Companies Continued to Realize Investment Returns, Accretive to the Group's Profits

继续部分退出孵化组合公司，实现投资回报，增加集团利润

During the Reporting Period, the Company achieved partial investment exits from a number of portfolio companies (Focus-X, Saverna, Dogma, Riparian, DTX and Nerio), realizing corresponding investment returns and generating total proceeds of nearly

在报告期内，公司实现了对若干被投企业（Focus-X、Saverna、Dogma、Riparian、DTX 和 Nerio）的部分投资退出，获得了相应的投资回报，总收益近

RMB162.5 million

人民币1.625亿元

. As of

. 截至

December 31, 2024

2024年12月31日

, the Group had invested in a total of 93 portfolio companies. The portfolio companies are mainly from

，该集团已总共投资了93家投资组合公司。这些投资组合公司主要来自

the United States

美国

,

，

Canada

加拿大

,

，

Europe

欧洲

and

和

China

中国

. 67.7% of the portfolio companies are from

67.7%的投资组合公司来自

North America

北美

and 25.8% are from

并且25.8%来自

China

中国

.

。

In 2024, 11 of the Company's portfolio companies completed or were close to completing a new round of financing, raising approximately

2024年，公司投资组合中的11家公司已完成或接近完成新一轮融资，共计筹集约

US$292.7 million

2.927亿美元

. The R&D efforts of the portfolio companies were advancing smoothly, with the total number of pipeline projects reaching close to 227, of which 186 pipelines are in the preclinical stage and 41 pipelines in the clinical stage. So far, the Group has successfully realized 15 investment exits or partial exits.

组合公司研发进展顺利，合计管线总数接近227个，其中临床前管线186个，临床管线41个，集团目前已成功实现15个项目投资退出或部分退出。

Furthermore, the Group may have several potential exits of our portfolio companies, and it also can be foreseen that a peak season of investment exits will arrive in the next three years..

此外，集团有多个投资组合公司潜在退出机会，预计未来三年将迎来投资退出的高峰。

As of

截至

December 31, 2024

2024年12月31日

, the Company has strategically invested in a series of high-quality assets, including portfolio companies such as Haya, Mediar, Nerio, Full-Life, Absci, Dogma, Arthrosi, Basking, Cybrexa and FuseBio. In the future, as these portfolio companies to develop successfully, secure ongoing financing, and realize exits, the initial investments will gradually enter the harvesting phase, providing sustained cash returns and investment income for the Group. .

公司战略性投资了一系列高质量资产，包括Haya、Mediar、Nerio、Full-Life、Absci、Dogma、Arthrosi、Basking、Cybrexa和FuseBio等被投企业。未来，随着这些被投企业的顺利发展、持续融资及退出的实现，初始投资将逐步进入收获期，为集团提供持续的现金回流与投资收益。

Technology Highlights and R&D Breakthroughs

技术亮点与研发突破

Viva Biotech's artificial intelligence technology, accumulated and developed over many years, is empowering its entire drug discovery platform. The current AI capabilities cover the full workflow of FIC drug discovery and are gradually transforming the logical paradigm of drug discovery through end-to-end integration.

维亚生物经过多年积累开发的人工智能技术，正在赋能其整个药物发现平台。目前的人工智能能力覆盖了FIC药物发现的整个工作流程，并通过端到端的整合逐步转变药物发现的逻辑范式。

By focusing on new targets, novel MOA and new modalities, Viva Biotech has developed distinctive AI capabilities, driving its one-stop innovative drug R&D service platform from 'AI-assisted' to 'AI-driven'..

通过聚焦新靶点、新机制和新形态，维亚生物已开发出独特的AI能力，推动其一站式创新药物研发服务平台从“AI辅助”走向“AI驱动”。

New Target

新目标

A series of target protein structures not reported in the PDB protein structure database have been delivered to customers.

已向客户交付了一系列未在PDB蛋白质结构数据库中报道的靶蛋白结构。

Novel MOA

新型作用机制

Including allosteric mechanisms, target selectivity and conformational selectivity. Comprehensive drug discovery technologies such as DEL, ASMS, Intact-MS, SPR, NMR, crystal soaking, virtual screening, membrane protein technology, phage display and HTS; as well as various experimental validation techniques including protein crystal structures, Cryo-EM structures, HDX-MS and Bioassay.

包含变构机制、靶标选择性和构象选择性。全面的药物发现技术如DEL、ASMS、Intact-MS、SPR、NMR、晶体浸泡、虚拟筛选、膜蛋白技术、噬菌体展示和高通量筛选（HTS）；以及包括蛋白质晶体结构、冷冻电镜结构、HDX-MS和生物测定在内的各种实验验证技术。

Additionally, the Company provides medicinal chemistry, computational chemistry, Pharmacology and DMPK services..

此外，公司还提供药物化学、计算化学、药理学和DMPK服务。

New Modality

新模态

Established platforms such as the XDC platform, peptide technology platform, PROTAC/molecular glue platform, and antibody/large molecule R&D technology platform.

已建立的平台包括XDC平台、多肽技术平台、PROTAC/分子胶平台以及抗体/大分子研发技术平台。

XDC Platform:

XDC平台：

Successfully integrated biologics/antibody platforms, peptide platforms, and small molecule drug platforms into the XDC large platform, covering multiple fields and capable of supporting various conjugated molecular models such as ADC, RDC, AOC, APC, DAC, etc. Additionally, the XDC platform has been deeply integrated with AIDD/CADD technologies and DEL technologies..

成功将生物药/抗体平台、多肽平台以及小分子药物平台整合入XDC大平台，覆盖多个领域，能够支持如ADC、RDC、AOC、APC、DAC等多种偶联分子模型。此外，XDC平台还与AIDD/CADD技术及DEL技术进行了深度融合。

Peptide Technology Platform:

肽技术平台：

At the peptide discovery journey, a new AI-based peptide generation method has been developed, as well as a peptide screening strategy combining DEL/phage display screening data with AI analysis capabilities. Through a multi-dimension peptide research and development approach, the success rate of customer peptide R&D has been comprehensively improved.

在多肽发现之旅上，开发了全新基于AI的多肽生成方法，以及结合DEL/噬菌体展示筛选数据与AI分析能力的多肽筛选策略。通过多维度的多肽研发手段，全面提升了客户多肽研发的成功率。

The company also provides one-stop peptide R&D and partial production services, including synthesis, biological testing, and PK research..

公司还提供一站式肽类研发和部分生产服务，包括合成、生物测试和药代动力学研究。

PROTAC/

PROTAC/

Molecular Glue Platform:

分子胶平台：

PROTAC/molecular glue-related services account for approximately 10.75% of the CRO's total revenue. Over 50 E3 ligases have been researched, and more than 150 PROTAC ternary complexes have been delivered.

PROTAC/分子胶相关服务约占CRO总收入的10.75%。已研究超过50种E3连接酶，并交付了150多个PROTAC三元复合物。

Macromolecular Drug/Antibody Platform:

大分子药物/抗体平台：

By combining AIDD/CADD technologies, multiple high-difficulty antibody affinity modification projects and patent breakthroughs have been successfully completed. Furthermore, the antibody R&D platform has been enhanced through the expansion and improvement of bispecific antibody design platforms, high-throughput antibody rapid expression platforms, mRNA immunization, gene gun immunization, and other technologies..

通过结合AIDD/CADD技术，成功完成了多个高难度的抗体亲和力改造项目并实现了专利突破。同时，通过拓展和完善双特异性抗体设计平台、高通量抗体快速表达平台、mRNA免疫、基因枪免疫等技术，进一步提升了抗体研发平台的能力。

AI-enabled SBDD One-Stop Novel Drug R&D Service Platform

人工智能驱动的SBDD一站式新药研发服务平台

The Company's AIDD and CADD platforms possess proprietary algorithms and platform-building capabilities, along with experience in developing various drug modalities. Leveraging Viva Biotech's strengths in structure-based drug R&D and supported by the computational power of the

公司的AIDD和CADD平台拥有自主算法和平台构建能力，并具备开发多种药物模式的经验。利用维亚生物在基于结构的药物研发方面的优势，并依托其强大的计算能力

Shanghai

上海

supercomputing cluster, these platforms comprehensively empower all stages of early drug development. Building on this foundation, Viva Biotech is transitioning from a phase where computational methods primarily supported various drug development stages to a new phase where AI drives drug design, integrates with experimentation, and transforms the drug design paradigm..

超算集群，全面赋能早期药物研发的各个环节。在此基础上，维亚生物正在从计算方法主要作为支持工具辅助各个药物研发环节的阶段，跨越到人工智能驱动药物设计、与实验结合并变革药物设计范式的阶段。

Staff and Facilities

职员与设施

As at

截至

December 31, 2024

2024年12月31日

, the Group had a total of 2,063 employees, of whom the number of CRO R&D personnel reached 1,121, and the headcount of Langhua Pharmaceutical was 711. The Company has well-established office and laboratory facilities in line, and is expanding production capacity to meet the fast-growing business needs, including:.

，集团共有员工2063人，其中CRO研发人员1121人，朗华制药员工人数711人。公司办公及实验室设施完善，并正在扩展生产能力以满足快速增长的业务需求，包括：。

The Group's headquarters in Zhoupu,

集团总部位于周浦，

Shanghai

上海

, with a total area of approximately 40,000 square meters.

，总面积约为40,000平方米。

The incubation center located in Faladi Road,

位于法拉迪路的孵化中心，

Shanghai

上海

has an actual usable area of approximately 7,576 square meters, including 5,552 square meters of laboratory area.

实际使用面积约为7576平方米，其中实验室面积为5552平方米。

The park in

公园在

Chengdu

成都

is approximately 64,564 square meters, of which 12,210 square meters of properties had been put into use as at

约为64,564平方米，其中12,210平方米的物业已在截至

December 31, 2024

2024年12月31日

, including 10,800 square meters of laboratory area.

，其中包括10800平方米的实验室面积。

A park in Suzhou is approximately 7,545 square meters, including nearly 5,305 square meters of laboratory area.

苏州的一个公园总面积约为7545平方米，其中实验室面积近5305平方米。

A park in Jiaxing is approximately 6,362 square meters, including nearly 5,335 square meters of laboratory area.

嘉兴的一个公园大约有6362平方米，其中包括近5335平方米的实验室面积。

Shanghai Supercomputing Center has been officially put into operation in 2021. At present, it can support computer-aided drug discovery (CADD) computation, artificial intelligence in drug discovery (AIDD) related computation, and crystal structure and Cryo-EM (Micro-ED) computation.

上海超级计算中心已于2021年正式投入运营，目前可支持计算机辅助药物设计（CADD）计算、人工智能药物发现（AIDD）相关计算以及晶体结构和冷冻电镜（Micro-ED）计算。

The factory of Langhua Pharmaceutical in Taizhou,

台州朗华制药厂

Zhejiang

浙江

is approximately 35,168 square meters, including the Taizhou R&D center with an area of approximately 2,500 square meters. The R&D center of Ningbo Nuobai has an area of approximately 1,300 square meters and the office building of Ningbo Nuobai has an area of approximately 1,500 square meters.

约为35,168平方米，其中包括台州研发中心，面积约为2,500平方米；宁波诺百的研发中心面积约为1,300平方米，宁波诺百的办公楼面积约为1,500平方米。

Dr.

博士

Mao Chen Cheney

毛陈切尼

, Chairman and Chief Executive Officer of Viva Biotech, said, 'With unique advantages in structure-based drug R&D (SBDD), the Company will increase the cross-sell between biological and chemical businesses, continue to strengthen the construction of a one-stop drug R&D and manufacturing service platform, deepen the synergy between CRO and CDMO business, improve the capacity building for front-end services and drive business to back-end services to further enhance the business funnel effect.

维亚生物董事长兼首席执行官表示：“公司凭借在基于结构的药物研发（SBDD）领域的独特优势，将增加生物与化学业务之间的交叉销售，继续加强一站式药物研发及生产服务平台建设，深化CRO与CDMO业务的协同效应，提升前端服务能力并推动业务向后端服务延伸，进一步强化业务漏斗效应。”

The Company is in an effort to establish an open eco-system for global biopharma innovators. '.

公司正努力为全球生物制药创新者建立一个开放的生态系统。

About Viva Biotech

关于维亚生物

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more.

成立于2008年的维亚生物（01873.HK）为全球生物医药创新者提供从基于结构的早期药物研发到商业化的全方位服务。我们通过整合专业的专家团队、尖端的技术平台以及在X射线结晶学、冷冻电镜、DNA编码化合物库、质谱筛选、表面等离子体共振、氢氘交换、人工智能/计算机辅助药物设计等领域的先进设备，提供从早期到后期药物发现的领先专业知识。

Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays.

我们的业务涵盖治疗策略和药物模式的各个方面，包括整个制药和生物技术领域的小分子和生物制品。经验丰富的化学团队由资深药物化学家和药物发现生物学家带领，为药物设计、药物化学（从苗头化合物到先导化合物及先导化合物优化）、定制合成、化学分析与纯化、千克级放大、肽合成及相应的生物测定提供服务。

With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs..

通过我们的子公司朗华制药，我们为全球制药和生物技术合作伙伴提供从临床前到商业化生产的一站式综合CMC（化学、制造和控制）服务。此外，Viva还为高潜力初创公司嵌入了股权换服务（EFS）模式，以满足未被满足的医疗需求。

As of

截至

December 31, 2024

2024年12月31日

, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,465 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world..

维亚生物已累计为全球2465家生物技术和制药客户提供药物研发和生产服务，投资孵化93家生物医药初创公司。未来，公司将持续加强技术壁垒、提升研发、生产水平与服务能力，为全球更多的药物发现初创公司以及中大型医药企业提供优质、多元化的服务。

SOURCE Viva Biotech

来源：维亚生物

WANT YOUR COMPANY'S NEWS

希望了解贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用